Sino Biopharmaceutical (HKG:1177) received positive Phase III clinical trial results for its non-small cell lung cancer (NSCLC) drug, according to a Wednesday filing with the Hong Kong bourse.
Benmelstobart Injection is sometimes used with Anlotinib Capsules for treating a specific type of lung cancer (Stage III non-small cell lung cancer) that cannot be removed or has advanced locally.
The interim analysis of the drug shows "primary study endpoint progression-free survival (PFS) has met the protocol's predefined superiority threshold."
The pharmaceutical has contacted China's Centre for Drug Evaluation about submitting a marketing application.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。